First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology firm focused on advancing antibody therapies. These innovative treatments are designed to modulate immune system pathways that contribute to autoimmune and inflammatory diseases. The company, founded in 2025, has its headquarters in San Diego, California, and operates as a subsidiary of AnaptysBio, Inc.